Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-008951
Filing Date
2023-05-10
Accepted
2023-05-10 06:16:01
Documents
59
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20230331x10q.htm   iXBRL 10-Q 1582472
2 EX-10.1 tbph-20230331xex10d1.htm EX-10.1 52185
3 EX-10.2 tbph-20230331xex10d2.htm EX-10.2 17943
4 EX-10.3 tbph-20230331xex10d3.htm EX-10.3 44089
5 EX-31.1 tbph-20230331xex31d1.htm EX-31.1 13462
6 EX-31.2 tbph-20230331xex31d2.htm EX-31.2 14239
7 EX-32 tbph-20230331xex32.htm EX-32 16233
  Complete submission text file 0001558370-23-008951.txt   5845328

Data Files

Seq Description Document Type Size
8 EX-101.SCH tbph-20230331.xsd EX-101.SCH 38901
9 EX-101.CAL tbph-20230331_cal.xml EX-101.CAL 53416
10 EX-101.DEF tbph-20230331_def.xml EX-101.DEF 161959
11 EX-101.LAB tbph-20230331_lab.xml EX-101.LAB 352239
12 EX-101.PRE tbph-20230331_pre.xml EX-101.PRE 265310
53 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20230331x10q_htm.xml XML 804708
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 23904206
SIC: 2834 Pharmaceutical Preparations